Strategy
MSTR
Meta Platforms
META
Oracle
ORCL
Amazon
AMZN
Salesforce
CRM
US Stock MarketDetailed Quotes
QTTB Q32 Bio
- 2.340
- -0.130-5.26%
Close Feb 26 16:00 ET
- 2.660
- +0.320+13.68%
Post 17:43 ET
28.50MMarket Cap-0.18P/E (TTM)
2.573High2.320Low141.40KVolume2.470Open2.470Pre Close337.49KTurnover3.65%Turnover RatioLossP/E (Static)12.18MShares53.79052wk High1.56P/B9.07MFloat Cap2.32052wk Low--Dividend TTM3.88MShs Float546.837Historical High--Div YieldTTM10.23%Amplitude2.320Historical Low2.386Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Q32 Bio Stock Forum
$Q32 Bio (QTTB.US)$
has options
nfa
$Q32 Bio (QTTB.US)$
$Richtech Robotics (RR.US)$
$SEALSQ Corp (LAES.US)$
$XTI Aerospace (XTIA.US)$
$MicroCloud Hologram (HOLO.US)$
$Q32 Bio (QTTB.US)$ reverse trend? get it before it's talked about, after a 50 percent gain day.... 22 percent shorts float.... they had some horrible news on december 11th. did there dip. most analysts have downgraded targets from $40-$50 down to $10-$20. which is still considerably higher than $4. looks to have consolidated around the 3-4. breaking the downward trend. I will be buying before the burst this week.... low shares low float. ... risky business is the name of the...
Worse than placebo for Eczema, ouch
Alopecia worked well, but probably people were looking for the eczema market?
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
Tuesday, 10th December at 4:05 pm
-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response --
-- SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet ...
No comment yet